Study schema. On enrolment in the study after eligibility assessment, patients were randomly assigned in a 1:1 fashion to receive either 60 mg DNM or placebo sc, every 6 months for 12 months for a total of 2 doses (Day 0 ± 3 and Day 180 ± 3). Patients were followed every 3 months for clinical and laboratory evaluation.